U.S. markets closed

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4600+0.0500 (+1.47%)
At close: 04:00PM EDT
3.6000 +0.14 (+4.05%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close3.4100
Bid3.6000 x 1300
Ask3.7800 x 2200
Day's Range3.3800 - 3.6100
52 Week Range2.1300 - 22.6800
Avg. Volume874,119
Market Cap212.647M
Beta (5Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-3.5640
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.72
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MGNX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MacroGenics, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/24/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    10 months agoArgus Research
View more
  • Motley Fool

    Why MacroGenics Stock Sank Today

    An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.

  • GlobeNewswire

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in September 2022: Citi 17th Annual BioPharma Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the Bispecifi

  • Simply Wall St.

    Brokers Are Upgrading Their Views On MacroGenics, Inc. (NASDAQ:MGNX) With These New Forecasts

    Shareholders in MacroGenics, Inc. ( NASDAQ:MGNX ) may be thrilled to learn that the analysts have just delivered a...